EOSE stock jumps nearly 10% as Eos tees up a Jan. 14 update — what investors are watching

EOSE stock jumps nearly 10% as Eos tees up a Jan. 14 update — what investors are watching

NEW YORK, Jan 13, 2026, 13:56 ET — Regular session

  • Shares of Eos Energy Enterprises climbed roughly 9% during Tuesday afternoon trading.
  • Traders highlighted positioning moves ahead of the company’s “Eos in Focus” webcast scheduled for Wednesday.
  • The stock showed volatility, trading on heavy volume with a broad intraday range.

Shares of Eos Energy Enterprises rose Tuesday, building on a recent streak ahead of the company’s webcast set for Wednesday.

The Nasdaq-listed battery maker has attracted quick traders this month, with its next catalyst set to drop before the bell. Some investors expect the event to shed new light on operations and funding, though others caution that the stock has already run hard, setting a tough benchmark.

Shares jumped roughly 9.2% to $17.62 in afternoon trading, having started the day at $16.54.

Eos announced it plans to hold an event called “Eos in Focus” on Wednesday, Jan. 14, following the company’s note about upcoming business updates this week. (Insider Monkey)

The company has scheduled the webcast for 8:30 a.m. ET on Wednesday. (Eose)

Tuesday saw the stock fluctuate from $16.21 up to $17.75, with over 20 million shares exchanged by mid-afternoon.

Eos develops and markets zinc-based energy storage systems, positioning them as a longer-duration alternative to lithium-ion. (Reuters)

Investors are now focused on one thing: clearer figures on execution. Concrete targets for production, deliveries, and cash flow could shift sentiment fast, especially following recent sharp daily swings.

But the situation works both ways. If Wednesday’s update lacks detail or signals delays, rising costs, or a bleaker outlook, the stock could quickly lose the gains it made, especially with how crowded this trade has grown.

The next key event is the “Eos in Focus” webcast at 8:30 a.m. ET on Wednesday. Investors will be digging into the company’s remarks for clues on how 2025 might shape up and what to expect in 2026. (Eose)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
Dow Jones Industrial Average drops from record as JPMorgan, Visa slide — what Wall Street watches next
Previous Story

Dow Jones Industrial Average drops from record as JPMorgan, Visa slide — what Wall Street watches next

Bloom Energy stock jumps as Korea AI data-center MoU puts fuel cells back in focus
Next Story

Bloom Energy stock jumps as Korea AI data-center MoU puts fuel cells back in focus

Go toTop